Cite
HARVARD Citation
Kulikowski, E. et al. (2017). Apabetalone (RVX-208) may lower CVD events in diabetes mellitus by affecting complement pathway and microbiome activity. Atherosclerosis. pp. e113-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kulikowski, E. et al. (2017). Apabetalone (RVX-208) may lower CVD events in diabetes mellitus by affecting complement pathway and microbiome activity. Atherosclerosis. pp. e113-. [Online].